全球血管指南:慢性肢体威胁性缺血的管理
该全球血管指南聚焦慢性肢体威胁性缺血(CLTI)的定义、评估和管理,推荐采用WIfI分期和客观血流动力学测试,提出基于患者风险、肢体严重程度和解剖复杂性的循证血运重建策略,并强调多学科团队和最佳药物治疗。
要点
- 疑似CLTI患者应紧急转诊至血管专科。
- 采用WIfI系统分期,趾压为 preferred 血流动力学指标。
- 循证血运重建基于PLAN三轴,GLASS分期评估解剖复杂性。
核心结论
- CLTI是临床综合征,需结合PAD与静息痛、坏疽或下肢溃疡>2周诊断。
- 推荐基于PLAN的循证血运重建,并强调最佳药物治疗和长期肢体监测。
研究设计与样本
- 全球血管指南由多学科专家制定,基于现有证据提出推荐。
主要发现
- 平均风险和高风险患者根据估计的手术和2年全因死亡率定义。
- GLASS通过定义首选目标动脉路径(TAP)并估计肢体通畅性(LBP)分为三个复杂性阶段。
- 非血运重建疗法(如脊髓刺激、气压治疗、前列腺素类、高压氧)的有效性尚未确立。
关键数值与推荐
- CLTI定义:PAD合并静息痛、坏疽或下肢溃疡>2周,排除静脉、创伤、栓塞和非动脉粥样硬化病因。
- WIfI系统基于伤口、缺血和足部感染分级。
- 趾压为评估CLTI的首选血流动力学指标。
- 平均风险和高风险患者由估计的手术和2年全因死亡率定义。
- GLASS分为三个复杂性阶段。
临床怎么用
- 所有CLTI患者应接受最佳药物治疗,包括抗血栓、降脂、降压和血糖控制药物,以及戒烟、饮食、运动和足部护理咨询。
- 血运重建策略需考虑自体静脉可用性,平均风险伴晚期肢体威胁和高复杂性病变可能首选静脉旁路,而解剖复杂性和肢体威胁程度较低或高风险患者可能倾向腔内治疗。
- 血运重建后建议长期肢体监测。
局限性
- 推荐基于现有最佳数据,尚待正在进行的试验提供1级证据。
- 再生医学方法(如细胞、基因治疗)应仅限于严格进行的随机临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.
引用
- Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019. PMID: 31159978. doi:10.1016/j.jvs.2019.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。